Welcome to our Evotec Blog.

Hope you will find our articles and resources relevant for your projects and interests.

Our experts are available for any additional information and to assist with your project challenges!

Just contact us.

 

 

2018

Evotec confirm closing of transaction with Sanofi to accelerate infectious disease research and development
Nerina Coppini, 3 July 2018

Hamburg, Germany, 03 July 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious disease research portfolio, has been successfully closed with...

Evotec and Sanofi sign definitive agreement to combat infectious diseases
Nerina Coppini, 18 June 2018

Acceleration of research and development (“R&D”) of novel anti-infectives 100 employees will join Evotec Sanofi will license more than 10 infectious disease (“ID”) R&D assets Sanofi to provide significant support to Evotec including a one-time, upfront payment of € 60 M to support progression of a next generation anti-infectives portfolio

 

 

Contact us

Evotec

Business Development

T +44.(0)1235.86 15 61 T +1.732 329 2355 x3308